Myasthenia gravis (MG) with antibodies to the muscle-specific receptor tyrosine kinase (MuSK) is a distinct sub-group of MG, affecting 5–8% of all MG patients. MuSK, a receptor tyrosine kinase, is expressed at the neuromuscular junctions (NMJs) from the earliest stages of synaptogenesis and plays a crucial role in the development and maintenance of the NMJ. MuSK-MG patients are more severely affected and more refractory to treatments currently used for MG. Most patients require long-term immunosuppression, stressing the need for improved treatments. Ideally, preferred treatments should specifically delete the antigen-specific autoimmune response, without affecting the entire immune system. Mucosal tolerance, induced by oral or nasal administration of an auto-antigen through the mucosal system, resulting in an antigen-specific immunological systemic hyporesponsiveness, might be considered as a treatment of choice for MuSK-MG. In the present study we have characterized several immunological parameters of murine MuSK-EAMG and have employed induction of oral tolerance in mouse MuSK-EAMG, by feeding with a recombinant MuSK protein one week before disease induction. Such a treatment has been shown to attenuate MuSK-EAMG. Both induction and progression of disease were ameliorated following oral treatment with the recombinant MuSK fragment, as indicated by lower clinical scores and lower anti-MuSK antibody titers.
|Journal||Frontiers in Immunology|
|State||Published - 17 Mar 2020|
Bibliographical noteFunding Information:
This work was supported by grants from The Association Francaise Contre les Myopathies (AFM), The European Commission (FIGHT-MG, contract # FP7 HEALTH-2009-242-210) and The Chief Scientist Office, Israel Ministry of Health to MS and SF.
© Copyright © 2020 Reuveni, Aricha, Souroujon and Fuchs.
- T regulatory cells
- muscle-specific receptor tyrosine kinase (MuSK)
- myasthenia gravis
- neuromuscular junction (NMJ)
- oral tolerance